TICKERNERD
Menu
EUDAEUDAReal Estate · Real Estate Services

EUDA Stock Forecast: EUDA Health Holdings Ltd. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$13
+2.52% on the day

The 1 Wall Street analysts covering EUDA Health Holdings Ltd. hold a median 12-month price target of $55 — +308.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 4 of 100 as at 10 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$39.3M
Ticker Nerd rank
4 / 100
Median analyst target
$55
Analysts covering
1
Total return, dividends reinvested
1W
−6.6%
1M
−11.7%
YTD
−70.9%
1Y
−42.5%
From 52W high
−82.7%
From 52W low
+155.7%
$5
$78
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

EUDA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores EUDA Health Holdings Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Sept 2026
4 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
84
Volatility
40
Momentum
26
Revisions
25
Value
17
Growth
16
Accruals
8
Quality
1
Issuance
0

Size (84): Smaller than most of the companies we track.

Issuance (0): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

EUDA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EUDA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Oct 25Jan 26Apr 26Jul 26EUDAHigh $55Median $55Low $55

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $55Median $55High $55

The green dot is the last close — the median target sits +308.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 Mar 2026Greenridge GlobalMaintainsBuy$6.00 → $2.75
9 Mar 2026Greenridge GlobalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EUDA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

EUDA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, EUDA Health Holdings Ltd. returned −42.5% against +17.5% for the S&P 500, dividends included.

EUDA vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150200250300350Oct 25Jan 26Apr 26Jul 26EUDAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

EUDA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−52.9%
Analysts raising
0
Analysts cutting
1
Fundamentals

EUDA Health Holdings Ltd. (EUDA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
30.0×

Cheaper than 25% of US stocks

Price / sales
5.8×

Cheaper than 22% of US stocks

Price / book
—
EV / EBITDA
−12.0×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
78.9%

Higher than 91% of US stocks

Earnings growth (YoY)
—
Gross margin
26.9%

Higher than 30% of US stocks

Operating margin
−34.8%

Higher than 19% of US stocks

Net margin
−40.7%

Higher than 12% of US stocks

Returns & dividend
Return on equity
65.0%

Higher than 94% of US stocks

Return on assets
−89.3%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

EUDA Health Holdings Ltd. (EUDA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • EUDA Health Holdings Ltd. has a market value of $39.3M and an enterprise value of $26.8M.

  • Shares outstanding: 1.9M.

  • Trailing P/E: 30.0×; forward P/E: 8.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • EUDA Health Holdings Ltd. employs 123 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2023 · market figures as at 11 Sept 2026

Data provided by Twelve Data

Peers

EUDA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelReal Estate Services
CompanyMarket capTKN rank
EUDAEUDA Health Holdings Ltd.$39.3M
4
ASPSAltisource Portfolio Solutions SA$66.0M
39
NYCAmerican Strategic Investment Co.$20.0M
70
DUOFangdd Network Group Ltd.$20.0M
22
FTHMFathom Holdings, Inc.$20.0M
24
MAYSJ.W. Mays, Inc.$80.9M
36
LHAILinkhome Holdings, Inc.$18.3M
8

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own EUDA Health Holdings Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EUDA news & analysis

EUDA Health Subsidiary Melana International Wins SME100 Awards 2026 Singapore

GlobeNewsWire · 26 Aug 2026positive

EUDA Health Holdings announced that its subsidiary, Melana International Pte. Ltd., was named one of the winners of the SME100 Awards 2026 Singapore, organised by Business Media International. The recognition was announced via a press release on August 26, 2026.

Why it matters — The award recognition highlights external acknowledgment of a EUDA subsidiary's performance, which is relevant for investors following the company's business across its markets.

EUDA Health Announces Collaboration to Advance an Integrated iPSC Cell Therapy Program for Oncology and Wellness • Targets global distribution for innovative Oncology products

GlobeNewsWire · 30 July 2026positive

EUDA Health announced a non-binding Memorandum of Understanding with GO POSB Organoids and Shenzhen Innovation Immunotechnology to pursue an integrated iPSC cell therapy program for oncology and wellness, targeting global distribution.

Why it matters — The collaboration signals EUDA's potential expansion beyond its core distribution business into advanced cell therapy for oncology and wellness markets.

EUDA Health Signs Important Tri-Party Memorandum of Understanding with GO POSB Organoids and Shenzhen Inno to Significantly Advance Next-Generation iPSC and NK-TCR Cell Therapies

GlobeNewsWire · 28 July 2026positive

EUDA Health Holdings Limited has signed a tri-party Memorandum of Understanding with GO POSB Organoids and Shenzhen Innovation Immunotechnology to collaborate on developing next-generation therapies derived from induced pluripotent stem cells (iPSC).

Why it matters — This MOU signals EUDA's expansion beyond its core distribution business into next-generation cell therapy research and development.

FAQ

Frequently asked questions about EUDA stock

What is the EUDA stock price forecast for 2026-2027?

The 1 Wall Street analysts covering EUDA Health Holdings Ltd. have a median 12-month price target of $55, with estimates ranging from $55 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EUDA stock a buy right now?

Of the 1 analysts covering EUDA Health Holdings Ltd., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks EUDA Health Holdings Ltd. 4 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EUDA?

As at 10 Sept 2026, EUDA Health Holdings Ltd. ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (84 of 100).

Will EUDA stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +308.9% from the last close, and Ticker Nerd's factor model ranks EUDA Health Holdings Ltd. 4 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EUDA stock forecast for 2030?

No analyst covering EUDA Health Holdings Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EUDA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $55 to $55 over the next 12 months.

How has EUDA stock performed over the past year?

EUDA Health Holdings Ltd. returned -42.5% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does EUDA Health Holdings Ltd. do?

EUDA Health Holdings Limited is a Singapore-based health technology and services company focused on non-invasive healthcare, preventive care, and wellness solutions across Southeast Asia and China. Its current offerings center on a digital healthcare ecosystem that uses artificial intelligence to assess patient histories, support triage, connect patients with clinicians, and coordinate care from wellness and prevention through urgent care, treatment, and aftercare.

What is the latest news on EUDA?

The most recent item we track (GlobeNewsWire, 26 Aug 2026): "EUDA Health Subsidiary Melana International Wins SME100 Awards 2026 Singapore". EUDA Health Holdings announced that its subsidiary, Melana International Pte. Ltd., was named one of the winners of the SME100 Awards 2026 Singapore, organised by Business Media International. The recognition was announced via a press release on August 26, 2026.

Company

About EUDA Health Holdings Ltd.

EUDA Health Holdings Limited is a Singapore-based health technology and services company focused on non-invasive healthcare, preventive care, and wellness solutions across Southeast Asia and China. Its current offerings center on a digital healthcare ecosystem that uses artificial intelligence to assess patient histories, support triage, connect patients with clinicians, and coordinate care from wellness and prevention through urgent care, treatment, and aftercare. The company also provides specialized medical services, including bioenergy cabin therapy packages, stem cell therapy services through third-party treatment centers, and holistic wellness consumer products and services. In addition, EUDA Health Holdings Limited operates property management services for residential, commercial, and retail properties, creating a diversified business model that combines healthcare and real estate-related operations. The company is headquartered in Singapore and serves both individual and corporate clients.

CEO Mr. Alfred Lim · 123 employees · Singapore · https://eudahealth.com